Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06180837

Effect of Sleep Extension on Ceramides in People with Overweight and Obesity

The overall goal is to determine how a sleep extension intervention (increasing time in bed) in individuals who maintain less than 6.5 hours sleep per night affects their plasma ceramides and insulin sensitivity. Participants will undergo a randomized controlled trial, with sleep extension (intervention) and healthy lifestyle (control) groups. The sleep extension is designed to increase participant's time in bed by 2 hours per night. Alternatively, the control group will receive basic health information (e.g., physical activity, goal setting, and nutrition when eating out).

Recruiting

Interested in participating?

Request Info

Key information

About this study

A randomized controlled trial with real-world sleep extension in adults with overweight and obesity who habitually obtain short sleep duration will be conducted. Group allocation will be 1:1 and research staff and participants will be blinded until the conclusion of the baseline segment. The sleep extension group will receive counseling and instruction to increase nightly time in bed by 2 hours per night. Participants randomized to control will maintain their habitual sleep habits in their home environment. The intervention segment will last 8 weeks regardless of group assignment. Both groups will have equal contact time with the study team.

Prior to enrollment participants will complete a clinical overnight sleep disorders screening. Baseline consists of an ~1-week ambulatory real-world monitoring segment. Following baseline, participants will be randomized 1:1 to either the sleep extension or control group for 8 weeks at home (intervention segment). Throughout the study, sleep duration will be monitored using an actiwatch wrist-device and a daily electronic sleep log. Following the baseline and intervention segments participants will complete rigorous overnight laboratory visits to assess plasma ceramides (targeted metabolomics assay) and insulin sensitivity (hyperinsulinemic-euglycemic clamp).

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age: 18-45 years old; equal numbers of men and women
  • Body mass index (BMI): 27.5-34.9 kg/m2
  • Sleep Habits: habitual self-reported average total sleep time (TST) <6.5 hours per night for prior 6 months

Exclusion criteria

  • Clinically diagnosed sleep disorder or major psychiatric illness
  • Evidence of significant organ dysfunction or disease (e.g., heart disease, kidney disease)
  • Clinically diagnosed diabetes or fasting plasma glucose ≥126 mg/dL or HbA1c ≥6.5%
  • Use of prescription drugs or substances known to influence sleep or glucose metabolism, or anticoagulant medications.
  • Cancer that has been in remission less than 5 years
  • Pregnant/nursing, experiencing menopause or post-menopausal
  • Shift-work: current or history of within last year
  • Weight change: >10% of body weight over prior six months
  • Current enrollment in weight loss or physical activity program like the Diabetes Prevention Program
  • Currently smoking
  • Alcohol intake>14 drinks per week or >3 drinks per day

Treatment and study plan

sleep extension intervention

Behavioral

Sleep extension-based intervention focused on increasing time spent in bed by 2 hours per night by directly scheduling assigned bed and waketimes based on participant's individual schedules. Participants will receive weekly sleep tips and counseling on improving their sleep duration.

Primary outcomes

  1. Total Plasma Ceramides

    Time frame: Immediately after the intervention

    Total plasma ceramides will be measured by assessing plasma ceramides by targeted metabolomics.

  2. Insulin Sensitivity

    Time frame: Immediately after the intervention

    Insulin sensitivity will be measured by the glucose infusion rate per kg body weight during the hyperinsulinemic-euglycemic clamp.

Secondary outcomes

  1. Average (per week) nightly total sleep time (change from baseline)

    Time frame: Analyzed as change from baseline for each week of the ~8 week experimental segment

    Wrist-actigraphy

  2. Average (per week) sleep satisfaction change from baseline

    Time frame: Analyzed as change from baseline for each week of the ~8 week experimental segment

    5 point likert scale on daily sleep log (1 = very good; 5 = very poor)

  3. Average (per week) timing of food intake change from baseline

    Time frame: During the baseline ambulatory assessment and weeks 2, 4, 6, and 8 of the intervention ambulatory assessment.

    Time of day 50% of calories are consumed collected by picture based food diaries. Average per week will consist of two weekdays and one weekend day

  4. Average (per week) daytime alertness change from baseline

    Time frame: Time Frame: Analyzed as change from baseline for each week of the ~8 week experimental segment

    5 point likert scale on daily sleep log (1= most alert; 5 = not alert at all)

  5. Individual C16, C18, C20, C22, C24, and C24:1 Plasma Ceramides, Dihydroceramides, Glucosylceramides, and fourteen Sphingolipids.

    Time frame: Immediately after the intervention

    Targeted metabolomics assay, 32 total metabolites.

  6. Circadian Phase (change from baseline)

    Time frame: Immediately after the intervention

    dim-light melatonin onset quantified from salivary melatonin samples

  7. Body Mass Index

    Time frame: Immediately after the intervention

    Nurses will collect height and body weight using standard procedures.

  8. Cardiac Event Risk Test 1 (CERT 1)

    Time frame: Immediately after the intervention

    The Cardiac Event Risk Test 1 (CERT1) is used to evaluate the risk of major adverse cardiovascular events and can be calculated using data from our targeted metabolomics assay. The scale is from 0-12, 0 being the lowest risk and 12 being the highest level of risk.

Study contacts

Contact information is provided by the study sponsor or research team.

Christopher M Depner, PhD

CONTACT

[email protected]

801-581-2275

Sponsors and collaborators

Lead sponsor

University of Utah

Other

Registry information

Official study title

Biomarkers of Habitual Short Sleep and Related Cardiometabolic Risk

Important dates

Study start
2024
Primary completion
2028
Study completion
2028
First posted
Dec 26, 2023
Registry last updated
Dec 20, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.